PeopleMark R
Mark R
Mark R. BamforthNon-executive DirectorMark Bamforth is a Non-Executive Director at Pneumagen.Mark has founded, grown and sold three contract development and manufacturing organizations (CDMOs): Arranta Bio (acquired by Recipharm in 2022), Brammer Bio (acquired by Thermo Fisher Scientific in 2019) and Gallus BioPharmaceuticals (acquired by DPx Holdings in 2014). He was previously at Genzyme Corp. for 22 years, where he latterly led global manufacturing operations.Mark is an active investor in the healthcare and life sciences sector, serving as a General Partner in the Kineticos AMR Fund I. He currently serves on the boards of Continuus Pharma, Enterobiotix, Entrepreneurial Scotland Foundation, Inceptor Bio, and Pneumagen. He previously sat on multiple CDMO, biotech and trade association boards.Mark holds an MBA from Henley Management College and a BS in Chemical Engineering from Strathclyde University.
active0
Roles
team_member
Timeline
Current Company
